Corticosteroid therapy associated with COVID-19 : an ally or a risk factor for the establishment of secondary fungal co-infections?
dc.contributor.author | Amaral, Thaís Ferreira do | pt_BR |
dc.contributor.author | Coutinho, Natália Monteiro da Silva Rodrigues | pt_BR |
dc.contributor.author | Fuentefria, Rubia do Nascimento | pt_BR |
dc.contributor.author | Fuentefria, Alexandre Meneghello | pt_BR |
dc.contributor.author | Machado, Gabriella da Rosa Monte | pt_BR |
dc.date.accessioned | 2024-01-11T03:25:20Z | pt_BR |
dc.date.issued | 2022 | pt_BR |
dc.identifier.issn | 2357-9730 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/270831 | pt_BR |
dc.description.abstract | Corticosteroid therapy to combat inflammation caused by SARS-CoV-2 seems to be a risk factor for developing secondary fungal co-infections. PubMed and ScienceDirect databases were searched, with the following word groups: [(aspergillosis OR mucormycosis OR candidiasis) AND (coronavirus disease) AND (corticoids). The selected articles present the main risk factors related to the establishment of secondary fungal co-infections in COVID-19 patients. Corticosteroid therapy used to combat inflammation caused by SARS-CoV-2 has been shown to be strongly associated with the establishment of mucormycosis and aspergillosis. Mucormycosis has been the main fungal co-infection related to corticosteroid therapy, causing a high number of deaths in COVID-19 patients. Diabetes mellitus was the most prevalent comorbidity, especially for the establishment of mucormycosis. Dexamethasone use seems to be associated with mucormycosis emergence and death. However, aspergillosis showed a greater relationship with patient recovery. Thus, risk factors such as diabetes mellitus, combined with corticosteroid use, have shown a relationship to the establishment of mucormycosis. The corticosteroids used in COVID-19 patients should be individually analyzed, considering the patient’s medical history and the risk/benefit ratio of the use of these drugs. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Clinical and biomedical research. Porto Alegre. Vol. 42, no. 4 (2022), p. 369-377 | pt_BR |
dc.rights | Open Access | en |
dc.subject | Fungal co-infections | en |
dc.subject | Corticosteróides | pt_BR |
dc.subject | Mucormycosis | en |
dc.subject | Efeitos adversos | pt_BR |
dc.subject | COVID-19 | pt_BR |
dc.subject | Aspergillosis | en |
dc.subject | Tratamento farmacológico da COVID-19 | pt_BR |
dc.subject | Corticotherapy | en |
dc.subject | Aspergilose | pt_BR |
dc.subject | Coinfecção | pt_BR |
dc.subject | Mucormicose | pt_BR |
dc.title | Corticosteroid therapy associated with COVID-19 : an ally or a risk factor for the establishment of secondary fungal co-infections? | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001193068 | pt_BR |
dc.type.origin | Nacional | pt_BR |
Este item está licenciado na Creative Commons License
![](/themes/Mirage2Novo//images/lume/cc.png)
-
Artigos de Periódicos (39402)Ciências da Saúde (10592)